Patients who had first been examined between January 2009 and December 2012 at Seoul Saint Mary's Hospital Glaucoma Clinic were considered as study participants. All subjects underwent a complete ophthalmic examination at baseline: visual acuity assessment, refraction, slit lamp biomicroscopy, gonioscopy, Goldmann applanation tonometry (Haag-Streit), dilated funduscopic examination, standard automated perimetry (Humphrey VF Analyzer; 30–2 Swedish Interactive Threshold Algorithm; Carl Zeiss Meditec, Inc., Dublin, CA, USA), central corneal thickness by ultrasound pachymetry (Tomey Corporation, Nagoya, Japan), axial length with ocular biometry (IOLMaster; Carl Zeiss Meditec, Inc.), stereo disc photography and red-free retinal nerve fiber layer (RNFL) photography (Canon, Tokyo, Japan). Patients who followed up for more than 4 years at 6- to 12-month intervals and had five or more reliable VF examinations were included in this study by a retrospective medical record review in September 2018. Additionally, they were subjected to three-dimensional, volumetric scans using SSOCT (DRIOCT Triton; Topcon Corporation, Tokyo, Japan) at their visit in 2017 to 2018.
The diagnosis of NTG was based on the following criteria: typical glaucomatous optic neuropathy disc changes (such as localized or diffuse rim thinning, disc hemorrhage, and notch in the rim) as seen on stereo disc photography; typical glaucomatous RNFL changes as seen on either stereo disc photography or red-free RNFL images; corresponding glaucomatous VF loss; open anterior chamber angles (>180° visible pigmented posterior trabecular meshwork on nonindentation gonioscopy in primary position); and normal untreated IOP level (≤21 mm Hg). Glaucomatous VF defect diagnoses were made based on the following criteria: glaucoma hemifield test outside normal limits results or the presence of at least three contiguous test points within the same hemifield on the pattern deviation plot at P value less than 5% with at least one of these points less than 1%, confirmed by two consecutive reliable tests (fixation loss rate ≤20% as well as false-positive and false-negative error rates ≤15%).
Patients were excluded from the study when they met one or more of the following criteria: best-corrected visual acuity less than 20/40; an emmetropic or hyperopic eye with the axial length les than 24.0 mm and spherical equivalent exceeding 0 diopters; a history or evidence of optic neuropathies other than glaucoma or congenital anomalies of the optic disc; signs of pathologic myopia including myopic choroidal neovascularization, lacquer crack, angioid streaks; extremely myopic eyes with an axial length >30 mm or evident posterior staphyloma; history of ocular surgery (other than uncomplicated cataract surgery); any other systemic or ocular pathology known to affect the optic disc, RNFL, or VF (e.g., retinal vascular occlusive disease, diabetic retinopathy, hypertensive retinopathy, uveitis, previous or current use of systemic or topical steroids); and eyes with poor image quality of the OCT scan that was not delineated clearly. Eligibility was determined by two glaucoma specialists (YCK and KIJ), who evaluated the optic disc appearance using stereoscopic disc photography, RNFL defects based on red-free fundus photography, and the results of VF examinations. Both evaluators were masked to all patient systemic and ocular data. Eyes were excluded from the study analyses if a consensus was not reached. When both eyes were eligible, one eye was selected randomly in each subject for data analysis.